These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 8831760

  • 1. 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.
    Bhatia PA, Brooks CD, Basha A, Ratajczyk JD, Gunn BP, Bouska JB, Lanni C, Young PR, Bell RL, Carter GW.
    J Med Chem; 1996 Sep 27; 39(20):3938-50. PubMed ID: 8831760
    [Abstract] [Full Text] [Related]

  • 2. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME, Capetola RJ.
    J Pharmacol Exp Ther; 1994 Dec 27; 271(3):1399-408. PubMed ID: 7996452
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
    Rao PN, Chen QH, Knaus EE.
    J Med Chem; 2006 Mar 09; 49(5):1668-83. PubMed ID: 16509583
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of maesanin and analogs on arachidonic acid metabolizing enzymes.
    Abourashed EA, Muhammad I, Resch M, Bauer R, el-Feraly FS, Hufford CD.
    Planta Med; 2001 Jun 09; 67(4):360-1. PubMed ID: 11458456
    [Abstract] [Full Text] [Related]

  • 5. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
    Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.
    J Med Chem; 1997 Aug 29; 40(18):2866-75. PubMed ID: 9288168
    [Abstract] [Full Text] [Related]

  • 6. Celecoxib inhibits 5-lipoxygenase.
    Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, Metzner J, Groesch S, Pergola C, Steinhilber D, Werz O, Geisslinger G.
    Biochem Pharmacol; 2008 Oct 01; 76(7):862-72. PubMed ID: 18692027
    [Abstract] [Full Text] [Related]

  • 7. 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide analogues.
    Mano T, Stevens RW, Okumura Y, Kawai M, Okumura T, Sakakibara M.
    Bioorg Med Chem Lett; 2005 May 16; 15(10):2611-5. PubMed ID: 15863327
    [Abstract] [Full Text] [Related]

  • 8. 1'-Hydroxyeugenol- and coniferyl alcohol derivatives as effective inhibitors of 5-lipoxygenase and Cu(2+)-mediated low density lipoprotein oxidation. Evidence for a dual mechanism.
    Deigner HP, Wolf G, Ohlenmacher U, Reichling J.
    Arzneimittelforschung; 1994 Aug 16; 44(8):956-61. PubMed ID: 7945541
    [Abstract] [Full Text] [Related]

  • 9. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
    Delorme D, Ducharme Y, Brideau C, Chan CC, Chauret N, Desmarais S, Dubé D, Falgueyret JP, Fortin R, Guay J, Hamel P, Jones TR, Lépine C, Li C, McAuliffe M, McFarlane CS, Nicoll-Griffith DA, Riendeau D, Yergey JA, Girard Y.
    J Med Chem; 1996 Sep 27; 39(20):3951-70. PubMed ID: 8831761
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation.
    Ergün BC, Nuñez MT, Labeaga L, Ledo F, Darlington J, Bain G, Cakir B, Banoglu E.
    Arzneimittelforschung; 2010 Sep 27; 60(8):497-505. PubMed ID: 20863006
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma.
    Chabot-Fletcher MC, Underwood DC, Breton JJ, Adams JL, Kagey-Sobotka A, Griswold DE, Marshall LA, Sarau HM, Winkler JD, Hay DW.
    J Pharmacol Exp Ther; 1995 Jun 27; 273(3):1147-55. PubMed ID: 7791085
    [Abstract] [Full Text] [Related]

  • 12. [Inhibition of the arachidonic acid cascade by aza-2-aryl-1,4-naphthoquinone derivatives].
    Richwien A, Wurm G.
    Pharmazie; 2004 Dec 27; 59(12):906-12. PubMed ID: 15638076
    [Abstract] [Full Text] [Related]

  • 13. [Lipoamino acids and lipopeptides as potential 5- and 12-lipoxygenase inhibitors].
    Presenz P.
    Pharmazie; 1997 Feb 27; 52(2):164-5. PubMed ID: 9122277
    [No Abstract] [Full Text] [Related]

  • 14. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
    Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL, Carter GW.
    J Med Chem; 1997 Feb 28; 40(5):819-24. PubMed ID: 9057869
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH, Rao PN, Knaus EE.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7898-909. PubMed ID: 16904331
    [Abstract] [Full Text] [Related]

  • 16. [Pyrano[3,4-c]quinolines from 1-desaza--oxa-nifedipine].
    Görlitzer K, Trittmacher J, Jones PG, Frohberg P, Drutkowski G.
    Pharmazie; 2003 Aug 01; 58(8):539-42. PubMed ID: 12967028
    [Abstract] [Full Text] [Related]

  • 17. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase.
    Crawley GC, Bird TG, Bruneau P, Dowell RI, Edwards PN, Foster SJ, Girodeau JM, McMillan RM, Walker ER, Waterson D.
    J Lipid Mediat; 1993 Aug 01; 6(1-3):249-57. PubMed ID: 8395247
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T, Argentieri DC, Barbone AG, Singer M, Steber M, Ansell J, Beers SA, Wachter MP, Wu W, Malloy E, Stewart A, Ritchie DM.
    J Pharmacol Exp Ther; 1997 Aug 01; 282(2):1094-101. PubMed ID: 9262379
    [Abstract] [Full Text] [Related]

  • 19. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 01; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 20. Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase.
    Araico A, Terencio MC, Alcaraz MJ, Domínguez JN, León C, Ferrándiz ML.
    Life Sci; 2006 May 15; 78(25):2911-8. PubMed ID: 16360707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.